Immunogenic cell death-related classification to predict prognosis and immunotherapeutic response in hepatocellular carcinoma

Abstract

Immunogenic cell death (ICD) has been classified as a form of regulated cell death (RCD) sufficient to activate adaptive immune responses. There is growing evidence that ICD is capable of reshaping the tumor immune microenvironment through the release of danger signals or DAMPs, which may contribute to immunotherapy. Currently, identification of ICD-related biomarkers that allow patients to benefit from ICD immunotherapy would be of great help to classify patients. Here, we identified two subtypes associated with ICD by consensus clustering. high ICD subtypes were associated with good clinical outcome, immune cell infiltration and immune response signaling activity. In addition, we developed and validated an ICD-related prognostic model that predicted survival in HCC and correlated with the tumor immune microenvironment. In conclusion, we developed a new ICD subtype-based classification system for HCC. This classification has significant clinical outcomes for assessing prognosis and of immunotherapy of HCC patients.